We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-2.84%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.15B
AUM Growth
+$138M
(+6.9%)
Cap. Flow
+$87.9M
Cap. Flow
% of AUM
4.1%
Top 10 Holdings %
Top 10 Hldgs %
61.28%
Holding
37
New
9
Increased
9
Reduced
6
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$77.4M |
| 2 |
HCA Healthcare
HCA
|
+$75.9M |
| 3 |
Gilead Sciences
GILD
|
+$65.8M |
| 4 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$36.2M |
| 5 |
United Therapeutics
UTHR
|
+$34.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$95.3M |
| 2 |
Biogen
BIIB
|
+$94.6M |
| 3 |
NUVA
NuVasive, Inc.
NUVA
|
+$42.6M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$37.2M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$25.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.78% |
| 2 | Miscellaneous | 20.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
GSK
GSK
$101B
| $20M | 0.93% |
+400,000
| New | +$20.1M |
|
|
CYCN
27
DELISTED
Cyclerion Therapeutics
CYCN
| $17.9M | 0.83% |
+78,096
| New | +$22.1M |
|
28
TG Therapeutics
TGTX
$8.55B
| $8.65M | 0.4% |
+1,000,000
| New | +$7.56M |
|
29
Sutro Biopharma
STRO
$259M
| $6.83M | 0.32% |
60,000
| – | – |
|
30
Alkermes
ALKS
$7.73B
| $4.24M | 0.2% |
+188,281
| New | +$5.16M |
|
31
Surgery Partners
SGRY
$1.82B
| $1.3M | 0.06% |
160,084
| – | – |
|
|
32
Biogen
BIIB
$31.9B
| – | – |
-400,000
| Closed | -$94.6M |
|
|
EGRX
33
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| – | – |
-291,600
| Closed | -$14.7M |
|
|
NUVA
34
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-750,000
| Closed | -$42.6M |
|
|
CLVS
35
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-1,500,000
| Closed | -$37.2M |
|
|
GBT
36
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-1,800,000
| Closed | -$95.3M |
|
|
ELGX
37
DELISTED
Endologix Inc
ELGX
| – | – |
-930,001
| Closed | -$6.15M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Camber Capital Management held 37 positions worth $2.15B, up 6.9% from $2.01B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Camber Capital Management deployed $87.9M of net new capital in Q2 2019, opening 9 new positions and adding to 9 existing holdings. Its largest new stake was HCA Healthcare: 600,000 shares worth $81.1M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $25.8M trimmed.
- Camber Capital Management's largest Q2 2019 buy was HCA Healthcare: 600,000 shares worth $81.1M.
- Camber Capital Management added most to Viatris in Q2 2019, an estimated $77.4M increase.
- Camber Capital Management's biggest Q2 2019 reduction was Alexion Pharmaceuticals, cutting an estimated $25.8M.
- Camber Capital Management fully exited Global Blood Therapeutics, Inc. in Q2 2019, selling an estimated $95.3M.
- Camber Capital Management's ten largest holdings make up 61% of its $2.15B portfolio in Q2 2019.
- Camber Capital Management opened 9 new positions and closed 6 in Q2 2019.
- Camber Capital Management's portfolio value rose 6.9% quarter-over-quarter to $2.15B.
Based on Camber Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.